CD19 and non-Hodgkin lymphoma: These groundbreaking successes with CAR T cells directed to the B cell-specific antigen CD19 have attracted huge interest within both academia and the pharmaceutical industry, and in 2017, first approval of CAR T cell therapy was obtained by the U.S. Food and Drug Administration (FDA) for therapy of pediatric ALL and non-Hodgkin lymphoma (NHL).